Compartilhar
Informação da revista
Vol. 46. Núm. S3.
X Eurasian Hematology Oncology Congress
Páginas 17-18 (maio 2024)
Vol. 46. Núm. S3.
X Eurasian Hematology Oncology Congress
Páginas 17-18 (maio 2024)
PP 06
Acesso de texto completo
A CASE OF RECURRENT DIFFUSE LARGE B CELL NONHODGKIN LYMPHOMA WITH SKIN INVOLVEMENT
Visitas
695
Müzeyyen Aslaner Ak1, Birsen Sahip Yesiralioğlu1, Hatice Ayağ1, Pelin Ertop Doğan2, Şehmus Ertop1
1 Zonguldak Bülent Ecevit University Faculty of Medicine, Department of Haematology
2 Zonguldak Bülent Ecevit University Faculty of Medicine, Department of Dermatology
Este item recebeu
Informação do artigo
Resume
Texto Completo
Baixar PDF
Estatísticas
Figuras (2)
Suplemento especial
Este artigo faz parte de:
Vol. 46. Núm S3

X Eurasian Hematology Oncology Congress

Mais dados
Objective

Diffuse large B-cell lymphoma (DLBCL) is the most common histological subtype of non-Hodgkin lymphoma (NHL). Extra nodal involvement of B-cell lymphoma is usually seen in the gastrointestinal system, followed by the skin. Skin involvement of B-cell lymphomas can be primary or secondary. In this article, we aimed to present a case of DLBCL which did not have skin involvement before but showed recurrence with skin involvement.

Case report

A 77-year-old male patient presented with a diagnosis of DLBCL based on excisional LAP biopsy in the inguinal region conducted in November 2022. Laboratory tests revealed Hgb 14.3 g/dL, WBC 4.6 × 10^3/μL, plt 191 × 10^3/μL. Following 4 cycles of R-mini CHOP based on the stage 4 DLBCL diagnosis from PET-CT, interim PET-CT showed regression in existing lesions.

Methodology: The R-miniCHOP regimen was completed with 8 cycles. In December 2023, a nodular lesion with raised erythematous ground and vascularity in the temporal region was identified (Figure 1). Dermatological evaluation and biopsy revealed infiltration consistent with high-grade B-cell lymphoma. PET-CT detected increased FDG uptake (SUVmax: 10.13) in a soft tissue-density lesion in the right parietal region. Due to age and performance status, the patient was planned for Rituximab-Lenalidomide protocol.

Results: Starting from the 1st cycle, lesions showed regression, and by the 2nd week of the 1st cycle, complete disappearance of lesions was observed (Figure-2).

Conclusion: In conclusion, while NHL usually recurs in the same sites of involvement, widespread secondary cutaneous involvement has also been reported in the literature. In our patient who did not have primary skin involvement, disease recurrence occurred in the cutaneous region.In cases like ours, the optimal treatment option is salvage chemotherapy followed by autologous stem cell transplantation.

O texto completo está disponível em PDF
Baixar PDF
Idiomas
Hematology, Transfusion and Cell Therapy
Opções de artigo
Ferramentas